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Abstract
Background: Human cytomegalovirus (CMV) is one of the most commonly found agents of congenital infections.
Primary maternal infection is associated with risk of symptomatic congenital diseases, and high morbidity is frequently
associated with very low birth weight. Neonates with asymptomatic infection develop various sequelae during infancy.
This is the first Argentine study performed in neonates with congenital and postnatal HCMV infection. The purpose of
this study was to evaluate the performance of the polymerase chain reaction (PCR) technique with different pairs of
primers, to detect cytomegalovirus isolated in tissue cultures and directly in urine and dried blood spot (DBS) specimens.
Results were compared with IgM detection.
Methods: The study was performed between 1999 and 2001 on routine samples in the Laboratory. A total of 61 urine
and 56 serum samples were selected from 61 newborns/infants, 33 patients whose samples were analyzed during the
first two to three weeks of life were considered congenital infections; the remaining 28 patients whose samples were
taken later than the third week were grouped as perinatal infections, although only in 4 the perinatal transmission of
infection was determined unequivocally
Cytomegalovirus diagnosis was made by isolating the virus from urine samples in human foreskin fibroblast cells.
Three different primer pairs directed to IE, LA and gB genes were used for the HCMV PCR assay in viral isolates.
Subsequently, PCR and nested PCR (nPCR) assays with gB primers were performed directly in urine and in 11 samples
of dried blood spot (DBS) on Guthrie Card, these results were then compared with serology.
Results:  The main clinical manifestations of the 33 patients with congenital infection were purpura, jaundice,
hepatomegaly and anaemia. Three patients presented low birth weight as single symptom, 10, intracranial calcifications,
and 2, kidney failure. In the 28 patients grouped as with perinatal infection, anaemia, hepatosplenomegaly and enzymatic
alteration were predominant, and 4 patients were HIV positive.
The primers used to amplify the gB region had a PCR positivity rate of 100%, whereas those that amplified IE and LA
regions had a PCR positivity rate of 54% and 61% respectively, in CMV isolates.
Amplification by PCR of urine samples (with no previous DNA extraction), using primers for the gB region, detected 34/
61 positive samples. Out of the 33 samples from patients with congenital infection, 24 (73%) were positive. When nPCR
was used in these samples, all were positive, whereas in the remaining 28 patients, two negative cases were found.
Cytomegalovirus DNA detection in 11 samples was also carried out in DBS: 7 DBS samples were positive and 4 were
negative.
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Conclusions: Primers directed to the gB fragment region were the best choice for the detection of CMV DNA in
positive isolates. In congenital infections, direct PCR in urine was positive in a high percentage (73%) of samples; however,
in patients grouped as with perinatal infection only 36% of the cases were positive. With n-PCR, total sample positivity
reached 97%. PCR technique performed in DBS allowed identifying congenital infection in four patients and to be
confirmed in 3. These results show the value of nPCR for the detection of all cases of CMV infection. The assay offers
the advantage that it may be performed within the normal working day and provides reliable results in a much shorter
time frame than that required for either traditional tissue culture or the shell-viral assay.
Background
Human cytomegalovirus (CMV) is the viral agent most
frequently associated with congenital infections in man.
Although 90% of CMV congenitally infected infants are
asymptomatic at birth, approximately 10% develop
cytomegalic inclusion diseases, with a 20–30% mortality
rate [1]. However, up to age 2, 10–15% of asymptomatic
children develop neurological sequelae [2], such as sen-
sorineural hearing loss, mental retardation, motor defi-
cits, seizures and chorioretinitis. CMV has been observed
in infants born to mothers who were seropositive before
pregnancy [3,4]. Postnatal disease, though generally
asymptomatic, frequently occurs in infants with hepatic
involvement.
Several epidemiological studies on the incidence of the
virus and the long-term sequelae of congenital CMV infec-
tion have been carried out in the United States, UK and
Italy [5-7].
A vaccine against CMV is currently under development
[8,9], and new antiviral therapy for symptomatic new-
borns is under study [10].
Detection of CMV DNA by PCR amplification contributes
to a rapid and early diagnosis [11]. A large variety of prim-
ers have been used for the detection of CMV DNA by PCR,
but the problem to select suitable primers has prompted
studies in several laboratories, because the variations in
the viral genome sequence found in strains circulating in
diverse populations have been shown to affect the ability
of the reaction to detect CMV DNA [1,12,13].
We analysed the efficacy of three sets of primers that
amplify three different regions of CMV genomes for the
early diagnosis of CMV infections in a selected group of 61
newborns with congenital or perinatal infection. The best
conditions in terms of primers, to confirm the clinical sus-
picion of congenital or postnatal CMV infection, can be
established by tests on CMV isolates or by direct work on
urine samples. We performed the test on CMV isolates
with 80% of cytopathic effect to standardise the method
and ensure enough viral DNA so that PCR amplification
would not be conditioned by this factor. The results
herein presented allowed the selection of suitable gB
primers for PCR of urine and DBS samples and their cor-
relation with serology data.
Methods
Population
Sixty-one patients with positive virological results were
selected from a group of 237 newborns with signs and
symptoms compatible with HCMV diseases. Only 3 out of
33 congenital infection patients had low body weight as
sole symptom (Table 1). The series consisted of urine and
serum samples from 61 patients. Samples for congenital
infection diagnosis were collected at 1–21 days, and for
perinatal infection at 4.5 ± 3.5 months. Both samples
were collected simultaneously. CMV infection was con-
firmed by urine cultures performed during routine activi-
ties at our laboratory. Dried blood spots (DBS) were
collected from 11 babies, 3 during the early days of life,
and from the remaining 8, who were studied retrospec-
tively, at 24 days, 40 days, 34 days, 3 months, 2 at 5
months, 8 months and 20 months.
Congenital infection was diagnosed in 33 cases, while the
28 remaining cases were grouped as perinatal infections,
althugh they should be conceptually grouped as "congen-
ital or perinatal" infections, since in only 4 cases could the
perinatal origin of the infection be demonstrated by
analysing two samples, one taken at the time of birth and
the other when the disease was clinically manifest.
Virological Methods: Urine samples were processed in
parallel by PCR and culture, DBS by PCR and serum was
tested by solid-phase enzymatic immunoassay (Organon
Teknika).
Processing of clinical samples
Isolation of CMV in cell cultures and confirmation by an indirect 
immunofluorescence test
Two to 10 ml of urine were collected in sterile bags. A por-
tion was tested by culture and the rest was stored at -20°C
for direct PCR (with no previous DNA extraction).
For isolation of CMV, urine samples were pre-filtered
through 0.2-µm membranes, and inoculated (200 µl) in
PTP monolayers, a human foreskin fibroblast cell line
established by the Service of Tissue Culture (INEI, ANLISBMC Pediatrics 2004, 4 http://www.biomedcentral.com/1471-2431/4/11
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Table 1: Clinical findings in 61 infants with congenital and perinatal infection and specific IgM antibodies to Cytomegalovirus detected 
by enzymoimmunoassay
Congenital
Patient No Age (day/month) IgM Clinical and Laboratory data
1 5 d + IUGR, cerebral calcifications.
2 21 d - Ascites, renal problems, elevated liver enzymes.
3 6 d + SGA, purpura, hepatosplenomegaly
4, 8, 29 5 d, 5 d, 28 d -, +, + SGA
5 18 d + Petechiae, hepatosplenomegaly, jaundice
6, 14., 32 5 d, 8 d, 8 d +, +, + Hepatosplenomegaly, cerebral calcifications
7 14 d + Sepsis, thrombocytopenia.
9 20 m - AWGA, purpura, elevated liver enzymes.
10 5 d + SGA, cerebral microcalcifications, microcephaly
11 5 d - SGA, purpura, hepatosplenomegaly, thrombocytopenia
12 4 d - AWGA, purpura, elevated liver enzymes, trombocytopenia.
13 11 d + Sepsis, petechiae, thrombocytopenia
15, 21, 33 5 d, 5 d, 5 d -, +, - SGA, purpura, HIV+.
16 6 d - Cerebral calcifications, thrombocytopenia, HIV+ mother.
17 5 d + Foetal dystrophy, inclusion-bearing cells in urine.
18 14 d S/s IUGR, sepsis, foetal dystrophy
19 8 d + Hepatosplenomegaly, sepsis, died of hepatic failure
20 18 d + SGA, hydrocephalus, respiratory problems
22 3 m S/s Cerebral calcifications, congenital toxoplasmosis
23 24 d - Cholestasis, purpura, cerebral calcifications, elevated liver enzymes, sepsis.
24 5 d - Microcephaly, cerebral calcifications (irregular and punctate), thrombocytopenia
25 5 d + AWGA, hepatosplenomegaly, sepsis, jaundice.
26 3 m - Chorioretinitis
27 5 d - SGA, hepatosplenomegaly, petechiae, anaemia, cholestasis
28 5 d + SGA, purpura, cerebral calcifications, thrombocytopenia, splenomegaly, elevated liver enzymes
30 5 d + Hepatosplenomegaly, purpura
31 5 m - RNPT, AWGA, seizures, maturational delay, palsy at age one year
Perinatal
39 40 d - SGA, petechiae, hepatomegaly, respiratory problems.
41 5 m + HIV+, cerebral calcifications, hepatosplenomegaly, anaemia
47 34 d + Neonatal jaundice
50 8 m - SGA, Hepatosplenomegaly, elevated liver enzymes, anaemia, jaundice at age 2 months
Congenital or Perinatal
34, 37, 48 3 m, 8 m, 7 m -, -, S/s Hepatosplenomegaly, HIV+
35 4 m + Jaundice, biliary atresia
36 63 d + Anaemia, hepatosplenomegaly, malnutrition, hyperbilirubinemia
38, 43 4 m, 3 m -, - Petechiae, hyperbilirubinemia, splenomegaly
40 40 d - Ascitis, renal problems, elevated liver enzymes
42 42 d S/s SGA
44 3 m + Premature, scanty maternal contact
45 24 m - Malnutrition, pancytopenia.
46 12 m + Aplastic crisis
49 4 m + SGA, hepatosplenomegaly, jaundice, anaemia, petechiae.
51 2 m + Sepsis, cyanosis, vomiting
52 1 m S/s Petechiae, jaundice, anaemia, hepatosplenomegaly
53 5 m + Mental retardation, anaemia
54 2 m - RNPT, SGA, IUGR, anaemia, microcephaly, tricuspid valve insufficiency
55 3 m - SGA, rash, fever spikes
56, 58 5 m, 33 d -, - SGA, respiratory problems.
57 34 d + IUGR, sepsis, hepatomegaly, oesophageal atresia, elevated liver enzymes
59 26 d - SGA, HIV+ mother
60 38 d + IUGR, microcephaly, jaundice
61 6 m - Normal at birth, neutropenia
IUGR, intrauterine growth retardation; SGA, small for gestational age; AWGA, adequate weight for gestational age. S/s, sera not collectedBMC Pediatrics 2004, 4 http://www.biomedcentral.com/1471-2431/4/11
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Dr. Carlos G. Malbrán). Eagle's minimum essential
medium (Gibco) containing 2% foetal calf serum (Gibco)
was used to maintain the cell line. A 200-µl aliquot was
inoculated on a confluent monolayer of fibroblasts, and
then incubated at 37°C for up to 3 weeks. Eagle's was
replaced every 7 days, and fibroblasts were examined
every 48 h until appearance of typical viral cytopathic
effect. Positive cultures were suspended, washed with
phosphate buffer (PBS) and fixed with acetone. For direct
immunofluorescence, cells were incubated at 37°C for 45
min using a monoclonal antibody to CMV late antigen
(Whittaker, Bioprod and Chemicon Intl.), and washed.
Later, they were incubated at 37°C for 30 min in FITC-
labelled, anti-mouse rabbit serum (Dako), washed again,
and then observed by fluorescence microscopy.
Serology
The presence of CMV-IgM antibody was determined by an
enzyme-linked immunoabsorbent assay (Vironostika
anti-CMV IgM II, Organon Teknika), according to the
manufacturer's instructions.
CMV-PCR
Sample preparation
Tissue culture
CMV isolates with 80% of cytopathic effect in PTP cells
were treated with Trypsin–Versene, washed and sus-
pended in maintenance medium (MM). For DNA release,
1 ml of this suspension was heated at 55°C for 60 min
and then at 100°C for 7 min, and further centrifuged at
10,000 rpm for 3 min. The supernatant was transferred to
another Eppendorf tube and frozen at -80°C for at least 1
hour. Thus, it could be used as a template for PCR.
Urine
5 µl of each urine sample were directly amplified by n-
PCR (with no previous DNA release), with the primers
directed to the gB region. Negative samples were diluted
with sterile deionized water (50%), in order to dilute
inhibitors [1].
Blood Spots
The extraction of CMVDNA in DBS on Guthrie Cards
obtained from 11 neonates was performed following the
method of Shibata et al. [14] with the modifications intro-
duced by M. Barbi et al. [15].
Reaction
The PCR method for the detection of CMV was carried out
with previously described oligonucleotide primers for the
major immediate-early (MIE) fragment region (IV exon de
IE1, 242 pb [1,15], glycoprotein B (gB) gene (ORF UL55),
150 pb [11,16,17], and late antigen (LA) (ppUL83), 400
pb [1].
Table 2 shows the sequences of the oligonucleotide prim-
ers herein used. Reaction mixtures consisted of 5 µl of tar-
get DNA, 10 pmol of each oligonucleotide primer, for LA
primers 2.5 U/µl of enzyme Taq polymerase (Perkin-
Elmer Cetus, Nowalk) and 2.0 U/µl for gB and IE primers,
200 µM (each) of deoxynucleotide triphosphate, 5 µl of
10X reaction buffer (500 mM KCl, 10 mM tris-HCl, pH
8.3, 1.5 mM MgCl2, 0.01% gelatin), and high-pressure liq-
uid chromatography distilled water to a total volume of
50 µl in an Eppendorf tube. A negative control reaction
tube received only 50 µl of reaction mixture. A positive
control was carried out with the pattern strain kindly pro-
vided by Dr. María Barbi from the Istituto di Virologia,
Università degli Studi di Milano. Different cycles of ampli-
fication were carried out using a DNA thermocycler
(GeneAmp 2400, Perking-Elmer Cetus). Amplification
conditions were those described by the authors, with only
minor changes: region LA, 40 cycles of denaturation at
94°C for 105 sec, annealing at 65°C for 75 sec and exten-
sion at 72°C for 60 sec; each extension period was
increased by 10 sec on each subsequent cycle; region gB,
35 cycles of denaturation at 94°C for 15 sec, annealing at
58°C for 15 sec and extension 72°C for 15 sec; the second
amplification differed from the first in that 30 cycles were
performed and the annealing temperature was 50°C;
region IE, 35 cycles of denaturation at 94°C for 15 sec
annealing at 55°C. for 15 sec and extension 72°C for 15
sec. One initial denaturation at 94°C, 2 min and one final
extension at 72°C, 5 min were carried out in all
amplifications.
Aliquots (18 µl) of each PCR-amplified product were elec-
trophoresed on 2% agarose gel (Sigma A-7431) contain-
ing 0.5 µg/ml of ethidium bromide and were visualised
and photographed with UV light (Fig. 1).
Specificity of PCR reaction
These primers have previously failed to amplify other her-
pes viruses and cellular DNA.
PCR positivity rates of reaction
To estimate the PCR positivity rates, with the primers gB,
IE and LA relative to tissue culture, cells infected with the
pattern strain (Towne) were allowed to develop up to
80% cytopathic effect, and released DNA (as described in
sample preparation) was analysed by undiluted PCR and
with 1/50, 1/100,1/200, 1/300 and 1/400 dilutions.
Results
PCR positivity rates
Primers gB were amplified up to 1/300 dilution, primers
IE up to 1/100 and LA up to 1/50.BMC Pediatrics 2004, 4 http://www.biomedcentral.com/1471-2431/4/11
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Table 2: Sequences of oligonucleotide primers used for the amplification of HCMV genome
Primers Sequence (5-3)' Product Length (pb) Position in the gene References
IE tgaggataagcgggagatgt 242 1729–1748 Jiwa N et al. (1989)
actgaggcaagttctgcagt 1951–1970
gB Outer
accaccgcactgaggaatgtcag 150 1942–1966 Darlington et al. (1985)
tcaatcatgcgtttgaagaggta 2067–2091
inner
accaccgcactgaggaatgtcag 100 1967–1989
tcaatcatgcgtttgaagaggta 2066–2040
LA cacctgtcaccgctgctatatttgc 400 1967–1989 Demmler G et al. (1998)
caccacgcagcggcccttgatgttt 2066–2040
Ethidium bromide–stained agarose gel electrophoresis: analysis of DNA amplified with primers MIE, gB, LA Figure 1
Ethidium bromide–stained agarose gel electrophoresis: analysis of DNA amplified with primers MIE, gB, LA. Samples (M) the 
different newborns (M1, M2, M3, M4). MP 100 bp DNA markerBMC Pediatrics 2004, 4 http://www.biomedcentral.com/1471-2431/4/11
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PCR from CMV isolates
PCR from CMV positive cultures with gB primers were
positive in oll cases, unlike primers directed to the other
regions (Fig. 1); gB primer amplified 61/61 samples; IE
33/61 (12 congenital and 21 out of those grouped and LA
37/61 (19 congenital and 18 out of those grouped. Thus,
the PCR positivity rates of primers was 100% for gB, 54%
for IE, and 61% for LA.
PCR of urine samples using primers for the gB region
Definite PCR results using primers that amplify the gB
region in positive cell cultures was higher (61/61) than
those obtained by direct PCR (with no previous DNA
release) in urine samples from the same patients: 34/61
(56%), although 24 out of 33 patients with congenital
infection (73%) were positive (Table 3). When nPCR was
used in the same samples, 100% of patients with congen-
ital infection and 26 (93%) with samples grouped as peri-
natal infection were positive (Table 2).
PCR of (DBS) using primers for the gB region
Out of the 11 patients studied, 3 were newborn (pts. 6, 10
and 24), and out of the remaining 8, four aged, 20
months, 3 months, 24 days, and 5 months (pts. 9, 22, 23,
and 31) were positive, while the other four aged 40 days,
5 months, 34 days and 8 months (pts. 39, 41, 47 and 50)
were negative.
Discussion
Out of a group of 237 children of CMV infection, 61 sam-
ples were selected with positive isolation, 33 of which pre-
sented congenital infection, while the remaining 28 were
grouped as perinatal infection; although in only 4 could
perinatal infection be demonstrated and the other 24
could be either perinatal or congenital. The frequency of
positive cases in laboratory tests carried out was 14% (33/
237). of children with congenital infection, 4.66%
annual. This is a high frequency because the patients came
from a population of low economic resources with a high
seroprevalence of IgG for CMV, a result only explained by
the fact that all cases reaching our laboratory come from
suspected patients [18].
Amplification by PCR is frequently used in diagnostic lab-
oratories for the detection of CMV. As the choice of PCR
primers for CMV is crucial, three primer pairs were
selected from the literature, the IE and LA [1-12], which
amplify fragments of the early and late regions of the
genome respectively; and the gB [11,16,17], which ampli-
fies a fragment of the region that encodes the glycoprotein
B. These primers were designed from the pattern strains
AD169 and Towne, and they amplify genome regions that
are considered conserved, due to their functional proper-
ties. In order to unify the conditions of amplification,
CMV DNA extracted from cultures with an 80% of viral
cytopathic effect was used in all cases.
Several authors have found that the exon 4 region of the
IE gene was highly variable, and that nucleotide substitu-
tion was distributed along the gene [19,20]. These varia-
tions would result in alterations in the aa sequence of 12
positions (13%). The biological meaning of these varia-
tions is yet unknown.
Fewer studies have been conducted on LA primers. In
1988, Shibata et al. [21] amplified 28 samples of viral iso-
lates positive for CMV by PCR using IE and LA primers.
They found that one sample was amplified by the IE prim-
ers but not by the LA, whereas the other sample was
amplified by the LA primer but not by the IE.
In this study, the efficacy of LA primers in amplifying sam-
ples from newborns was higher than that of IE primers
(61% and 54%, respectively). Although these primers are
the most frequently used for laboratory diagnosis, the
results herein obtained indicate that their use is not advis-
able for the newborn population.
Differences in the PCR positivity rates of detection of the
viral genome among samples of patients studied by
diverse authors and those included in our study were
Table 3: Detection of HCMV by PCR/nPCR with gB primers in CMV isolates and urine
Samples Methods infection Positive (%) Total positive (%)
Positive culture PCR Congenital 33 (100) 61 (100)
Perinatal ** 28 (100)
Urine Direct PCR without DNA 
release
Congenital 24 (73) 34 (56)
Perinatal** 10 (36)
Urine n-PCR Congenital 33 (100) 59 (97)
Perinatal** 26 (93)*
* from the 3 negative samples, one of which became positive when a dilution was made ** samples grouped as perinatalBMC Pediatrics 2004, 4 http://www.biomedcentral.com/1471-2431/4/11
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probably due to the design of the primers. Even though
sensitivity with the diverse primers is variable (gB 1/300,
IE 1/100, LA 1/50), this factor would be negligible when
using an excess of virus unless the DNA release method
were efficient enough. Another factor to be considered is
that the number of passages in cell culture of viral isolates
analysed by PCR is too low to cause variations that could
affect the PCR reaction in conserved DNA sequences.
Sequencing of the IE and LA region of those strains that
failed to be amplified by the primers would confirm this
hypothesis.
In samples from studied patients, the PCR positivy rates
for gB with CMV isolates was 100% compared with the
gold-standard (tissue culture). Since gB primers were the
most suitable for the study of congenital infection in
Argentina, we attempted to determine whether these
primers were also effective when direct amplification
(with no previous DNA release) of urine samples was per-
formed in our patients. Viral genome was found in all
samples by nPCR (Table 3) but positive results were found
by PCR in 56% (34 patients) of the cases, including two
asymptomatic patients. On the other hand, in 33 congen-
ital infection patients, positive results were observed in
73% (24 patients), so that we may infer that in most cases
of congenital infection in symptomatic patients, CMV
infection may be detected by a single amplification in
urine. In these patients grouped as perinatal infection
there were three negative samples: one became positive
after dilution, and the other two were negative. This could
be associated with low viral elimination, sample altera-
tion during shipping or presence of inhibitory factors in
urine, since no purification was used. Samples from 11
patients were studied by DBS PCR at the time of birth, 8
of which were evaluated retrospectively, thus allowing the
congenital source of infection to be determined in four
cases. Likewise, 4 cases of perinatal infection were con-
firmed by this same technique.
Serology is a technique widely used in most laboratories,
despite its low sensitivity [18-22], so that it has also been
included in this study in order to discern the sensitivity of
the serological method used in our laboratory. However,
there were no significant differences between the serology
in patients with congenital infection and those grouped as
perinatal. Therefore, an accurate diagnostic method such
as PCR is highly advisable for the management of congen-
ital infection in new-borns during the first three weeks of
life. Viral isolation is very limited in our country due the
expense of specialised labour and the need of a special tis-
sue culture laboratory, so that PCR provides a valid
alternative.
Finally, given the large size of the CMV genome, and
despite the homogeneity among clinical isolates,
sequence studies should comprise more strains. More
importantly, there must be consensus on the type of prim-
ers to be used, since it has been demonstrated that slight
and sometimes silent variations in the sequence may alter
PCR sensitivity, thus leading to misdiagnoses.
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